Due to the potential of sAMLs to grow over time and the detrimental and costly long-term clinical outcomes for patients with large and/or multiple AMLs, there is an urgent need for therapies targeting a possible mTOR pathway in AML and for interventions that can prevent or delay the growth of AMLs without impairing the kidney. This evidence concerns the gene MTOR and acute myeloid leukemia.